ArticleJournal of experimental & clinical cancer research : CR2011
Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma.
Article in Journal of experimental & clinical cancer research : CR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 54 citations in OpenAlex.
- Whole blood expression profiling from the TREAT trial: insights for the pathogenesis of polyarticular juvenile idiopathic arthritis.Arthritis research & therapy · 2016Trial
- Activation of toll‑like receptors by non‑coding RNAs and their fragments (Review).Molecular medicine reports · 2025Review
- TLR9: A Double-Dealing Toll-Like Receptor.ImmunoTargets and therapy · 2025Review
- AGBL2 promotes renal cell carcinoma cells proliferation and migration via α-tubulin detyrosination.Heliyon · 2024Article
- Harnessing innate immune pathways for therapeutic advancement in cancer.Signal transduction and targeted therapy · 2024Review
- Inhibition of TLR7 and TLR9 Reduces Human Cholangiocarcinoma Cell Proliferation and Tumor Development.Digestive diseases and sciences · 2022Article
- Comprehensive Bioinformatics Analysis of Toll-Like Receptors (TLRs) in Pan-Cancer.BioMed research international · 2022Article
- The Role of Toll-like Receptors (TLRs) Mediated Inflammation in Pancreatic Cancer Pathophysiology.International journal of molecular sciences · 2021Review
- Prognostic Biomarker-Based Identification of Drugs for Managing the Treatment of Endometrial Cancer.Molecular diagnosis & therapy · 2021Article
- Toll Like Receptors as Sensors of the Tumor Microbial Dysbiosis: Implications in Cancer Progression.Frontiers in cell and developmental biology · 2021Review
- Article
- Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence.Clinical & experimental metastasis · 2020Review
- The Crosstalk Between Hippo-YAP Pathway and Innate Immunity.Frontiers in immunology · 2020Review
- The Role of TLRs in Anti-cancer Immunity and Tumor Rejection.Frontiers in immunology · 2019Review
- TLR9 signaling activation at different stages in colorectal cancer and NF-kappaB expression.OncoTargets and therapy · 2018Article
- Prognostic role of Toll-like receptors in cancer: a meta-analysis.Therapeutics and clinical risk management · 2018Article
- Toll-like receptor 5 and 7 expression may impact prognosis of HPV-positive oropharyngeal squamous cell carcinoma patients.Cancer immunology, immunotherapy : CII · 2017Article
- MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.Oncogene · 2017Article
- High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients.Virchows Archiv : an international journal of pathology · 2017Article
- Cell membrane and intracellular expression of toll-like receptor 9 (TLR9) in colorectal cancer and breast cancer cell-lines.Cancer biomarkers : section A of Disease markers · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundToll-like receptor 9 (TLR9) is a cellular DNA-receptor whose activation with cognate ligands triggers an immune reaction, with increased production of inflammatory cytokines. The aim of this study was to examine the expression of TLR9 in renal cell carcinoma (RCC), which is generally renowned of its immunogenic nature. We also evaluated the prognostic value of TLR9 in RCC.
methodsTLR9 expression in RCC was characterized with immunohistochemistry in a retrospective study population of 152 RCC patients who underwent renal surgery. The TLR9 staining intensity was compared with clinical parameters.
resultsOf the studied tumours, 112 (81%) exhibited cytoplasmic TLR9 immunostaining. No association was detected between cytoplasmic TLR9 immunoexpression intensity and stage, nuclear grade, histological subtype or tumour necrosis. Cytoplasmic TLR9 immunoexpression was, however, a marker of favourable RCC specific survival both in univariate analysis and in multivariate regression model.
conclusionsWe conclude that TLR9 expression is an independent prognostic marker of RCC and the absence of TLR9 expression is related to poorer prognosis in RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.